On CNBC's "Cramer's Mad Dash" segment, TheStreet's Jim Cramer, co-manager of the Action Alerts PLUS portfolio, took at look at this "classic growth stock."
The stock has had trouble gaining upside momentum due to rising coffee costs, he reasoned.
However, CEO Howard Schultz has had to deal with rising input costs before, and has well positioned his company to deflect this rapid rise.
Cramer added that investors are not paying too much for shares of Starbucks at current levels and he likes this analyst's call "very much."
Turning to Celgene (CELG), Credit Suisse boosted its price target on the stock to $225 from $210.
The analyst reasoned that Celgene's pipeline is not being fully recognized, and Cramer seemed to agree. The advancements in creating possible cures for Crohn's disease and psoriatic arthritis are incredible and could be huge for Celgene, he concluded.
-- Written by Bret Kenwell in Petoskey, Mich.